Mark Wainberg

Mark A. Wainberg, Director of the McGill AIDS Center at the Lady Davis Institute for Medical Research, was the first to identify the anti-HIV activity of 3TC, a compound that is now widely used in the treatment of both HIV disease and hepatitis B. He was also among the first to identify the problem of HIV drug resistance to AZT and other compounds and has been responsible for the mapping of mutation sites that encode resistance. His laboratory has also conducted mechanistic investigation of HIV drug resistance through studies on recombinant, purified mutated and wild-type HIV reverse transcriptase. He was the President of the International AIDS Society from 1998 to 2000.